DGAP-News: Sangui BioTech International Inc.: Granulox to enter Columbian market - SastoMed signs contract with distributor Colpharma
(firmenpresse) - DGAP-News: Sangui BioTech International Inc. / Key word(s): Alliance
Sangui BioTech International Inc.: Granulox to enter Columbian market
- SastoMed signs contract with distributor Colpharma
23.09.2013 / 10:00
---------------------------------------------------------------------
SanguiBioTech: Granulox to enter Columbian market - SastoMed signs contract
with distributor Colpharma
Witten, Germany, September 23, 2013
Colpharma Laboratorios S.A., Bogotá, Columbia, (www.colpharma.com.co) will
introduce the wound therapeutic Granulox to the Columbian market. An
agreement to this effect was signed with global Granulox licensee SastoMed
GmbH. In order to accomplish a fast market entry the necessary
authorizations are being obtained with the national authorities already.
Presentations of Granulox to the Columbian health system on the occasion of
Conferences and Congresses will start as early as November 2013. Actual
sales will start immediately after the authorization will have been passed.
Established in 1986, Colpharma sells and distributes all of its
pharmaceutical and medical products with a strong sales force on a national
level. The portfolio embraces 73 licensed and own brand products. The
company focuses on strategic cooperation with international pharmaceutical
groups, in order to upgrade the portfolio with outstanding innovative
products.
Elkin JoséCano, General Manager of Colpharma, emphasizes: 'Granulox with
its unique efficacy and fast healing time is definitely the most exciting
new product to be launched in Colombia. To be selected as its distributor
represents a major step forward in achieving our business growth
objectives. Colpharma will carry out all the necessary pre-marketing
activities in order to achieve a rapid and significant market penetration.'
'Columbia is one of the most exciting health markets in South America with
its 48 million inhabitants,, its solid economic growth for a row of
consecutive years now and steady ongoing improvements throughout the
medical sector', says Michael Sander, the Managing Director of SastoMed:
'We are glad to having contracted Colpharma: a strong and valuable partner
who is deeply rooted in the Colombian health system and pursues a
convincing growth strategy focusing on innovative products.'
Sangui BioTech International, Inc. ('SGBI') is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing(at)sangui.de
End of financial news
---------------------------------------------------------------------
23.09.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
231354 23.09.2013
Themen in dieser Pressemitteilung:
sangui-biotech-international-inc-granulox-to-enter-columbian-market
sastomed-signs-contract-with-distributor-colpharma
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="Soil Sampling Extends Potential Mineralized Zones by 600 Metres at Burro Creek, Arizona
Datum: 23.09.2013 - 10:00 Uhr
Sprache: Deutsch
News-ID 298943
Anzahl Zeichen: 4165
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 260 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Sangui BioTech International Inc.: Granulox to enter Columbian market - SastoMed signs contract with distributor Colpharma"
steht unter der journalistisch-redaktionellen Verantwortung von
Sangui BioTech International Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
